Van Der Doelen MJ, Kuppen MCP, Jonker MA, et al. Real world lessons for optimal selection of patients with bone metastatic castration-resistant prostate cancer for radium-223 therapy. EMUC 2017, P049.
Three-year Safety of Radium-223 in Patients with mCRPC and Symptomatic Bone Metastases
jul 2017 | Uro-oncologie